- Country profiles
- Data dashboard
- Satellite Pages
- About us
- WHAT'S NEW
Syphilis, a sexually transmitted bacterial infection, affects almost 40 million people worldwide. Like HIV, it can be passed from a pregnant woman to her unborn child. In pregnancy, if untreated, syphilis can result in severe outcomes for mother and infant. Yet, transmission can be effectively prevented with inexpensive and easily available penicillin treatment for pregnant women.6 Recognizing the opportunity to test and treat mothers and babies during antenatal or perinatal care, in 2007, the WHO and its partners published the Global elimination of congenital syphilis: rationale and strategy for action. The goal was to increase the number of pregnant women tested for syphilis to 90 per cent and to provide adequate treatment to at least 90 per cent of seropositive pregnant women by 2015.
See Regional Progress Hepatitis B Vaccination Coverage, 1990—2015, Regional Progress: Status of the 2017 Hepatitis B Control Milestone of <1% HBsAg Prevalence among 5 year old children
The sexual partners and drug injecting partners of people diagnosed with HIV infection have an increased probability of also being HIV-positive.
Communicable diseases such as HIV, TB and malaria remain among the leading causes of illness, death and impoverishment in our region, and infection levels continue to rise in many settings and populations. Unless focused efforts are undertaken to build on the gains to date, communities that remain vulnerable to neglected tropical diseases such as leprosy, kala-azar and filariasis will continue to be left behind. This report focuses on the historic opportunity for the WHO South-East Asia Region to end the scourge of communicable diseases for good.
Keywords: HIV, TB, malaria, neglected tropical diseases, public health
This manual for developing national action plans to address antimicrobial resistance has been developed at the request of the World Health Assembly to assist countries in the initial phase of developing new, or refining existing national action plans in line with the strategic objectives of the Global Action Plan. It proposes an incremental approach that countries can adapt to the specific needs, circumstances and available resources of each individual country. Details of actions to be taken will vary according to national contexts.
In this issue brief we first review trends in generic competition and intellectual property (IP) licensing for key antiretroviral drugs. We then outline seven momentous decisions to be made in 2015 that will largely determine whether ART will be affordable, available and robust for the next 15 years of treatment scale-up to all people living with HIV. This includes opportunities for greatly improved treatment regimens based on WHO guidelines on when to start treatment, and what first- and second line regimens should include.
Keywords: HIV/AIDS, Global Fund, medicines, treatment, ART
A survey was conducted in countries in all six WHO regions and focused on the building blocks that are considered prerequisites to combat antimicrobial resistance: a comprehensive national plan, laboratory capacity to undertake surveillance for resistant microorganisms, access to safe, effective antimicrobial medicines, control of the misuse of these medicines, awareness and understanding among the general public and effective infection prevention and control programmes.
The present document aims to review the progress of the HIV response in the Asia-Pacific region, with a view to identifying the opportunities for further action afforded by the 2011 Political Declaration. In doing so, it also draws on the expressed commitments undertaken by ESCAP member States to address the HIV epidemic, including those reflected in resolutions 66/10, Regional call for action to achieve universal access to HIV prevention, treatment, care and support in Asia and the Pacific (19 May 2010) and 67/9, Asia-Pacific regional review of the progress achieved in realizing the Declaration of Commitment on HIV/AIDS and the Political Declaration on HIV/AIDS (25 May 2011).
Keywords: IGM, 2015, HIV, prevalence, treatment, care, prevention, gender, violence, ART, children, women
The 10 case studies presented in this document clearly demonstrate that social protection works for HIV prevention, treatment, care and support. In particular, they show how social protection benefits the AIDS response through increased access to HIV services for all people including the most marginalized and excluded in society. The studies also demonstrate that carefully constructed and well-managed social protection programmes have the power to support people who are hardest to reach.
WHO guidelines on antiretroviral therapy (ART) have evolved during the past decade towards recommending earlier treatment, as evidence has shown clinical and public health benefit, treatment has become simpler, more tolerable and more affordable, and systems for ARV delivery have been streamlined for scale.
This update summarizes experiences of countries that have already begun to implement earlier treatment approaches as part of a national policy or pilot programmes. Overall, these five country examples demonstrate that scaling up a treat-all policy, across diverse populations (adults, key populations and children) is acceptable and feasible, with early benefits and no immediate evidence of harmful effects.